Search

Soliton’s (SOLY) Buy Rating Reiterated at Maxim Group

Soliton (NASDAQ:SOLY)‘s stock had its “buy” rating reissued by Maxim Group in a research note issued on Thursday, AnalystRatings.com reports. They presently have a $22.00 price objective on the stock. Maxim Group’s price objective would suggest a potential upside of 188.34% from the stock’s current price.


A number of other analysts also recently weighed in on SOLY. Zacks Investment Research downgraded shares of Soliton from a “buy” rating to a “hold” rating in a research report on Tuesday, May 26th. ValuEngine raised shares of Soliton from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. Finally, Roth Capital lifted their price target on Soliton from $14.00 to $16.00 in a research note on Tuesday, June 16th.


SOLY stock traded down $0.04 during trading on Thursday, reaching $7.63. The stock had a trading volume of 18,846 shares, compared to its average volume of 465,058. The firm has a fifty day moving average price of $10.77 and a 200 day moving average price of $10.63. The company has a market capitalization of $132.05 million, a P/E ratio of -7.60 and a beta of 0.19. Soliton has a 1-year low of $6.64 and a 1-year high of $21.97.


Soliton (NASDAQ:SOLY) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.06. On average, research analysts expect that Soliton will post -0.75 EPS for the current fiscal year.


In other Soliton news, major shareholder Remeditex Ventures Llc acquired 120,481 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was acquired at an average price of $8.30 per share, with a total value of $999,992.30. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 11.30% of the company’s stock.


A number of large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its position in Soliton by 24.8% in the first quarter. JPMorgan Chase & Co. now owns 8,896 shares of the company’s stock worth $72,000 after buying an additional 1,765 shares during the period. UBS Group AG lifted its position in Soliton by 38.5% in the 4th quarter. UBS Group AG now owns 6,841 shares of the company’s stock valued at $75,000 after purchasing an additional 1,903 shares during the last quarter. Matisse Capital acquired a new position in Soliton during the 1st quarter valued at about $108,000. Bank of New York Mellon Corp boosted its stake in Soliton by 19.0% during the 1st quarter. Bank of New York Mellon Corp now owns 17,560 shares of the company’s stock valued at $142,000 after purchasing an additional 2,804 shares during the period. Finally, Oxford Asset Management LLP acquired a new stake in shares of Soliton in the fourth quarter valued at approximately $209,000. Institutional investors and hedge funds own 11.81% of the company’s stock.


Soliton Company Profile

Soliton, Inc, an early stage medical device company, focuses on developing and commercializing products using a proprietary rapid acoustic pulse technology platform. It offers a device for the removal of tattoos. The company was founded in 2012 and is headquartered in Houston, Texas.


Source: https://weekherald.com/2020/07/02/solitons-soly-buy-rating-reiterated-at-maxim-group.html

Recent Posts

See All

Piccadilly Chambers
Dudley House
169 Piccadilly
London W1J 9EH

Phone +44 (0) 20 3858 3100

© 2020 by Falcon Capital LLP

Falcon Capital LLP (Registration No. OC320410 ) - Authorised and regulated by the Financial Conduct Authority